Immunomodulatory drugs: Oral and systemic adverse effects

被引:104
作者
Bascones-Martinez, Antonio [1 ]
Mattila, Riikka [2 ]
Gomez-Font, Rafael [3 ]
Meurman, Jukka H. [2 ]
机构
[1] Univ Complutense Madrid, Sch Dent, Dept Med & Bucofacial Surg, E-28040 Madrid, Spain
[2] Univ Helsinki, Cent Hosp, Inst Dent, Dept Oral & Maxillofacial Dis, Helsinki 08200, Finland
[3] Univ Complutense Madrid, Dept Med & Bucofacial Surg, E-28040 Madrid, Spain
来源
MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL | 2014年 / 19卷 / 01期
关键词
Immunomodulatory drugs; oral diseases; adverse effects; therapeutic action; INFLAMMATORY-BOWEL-DISEASE; PRIMARY SJOGRENS-SYNDROME; PLACEBO-CONTROLLED TRIAL; LUPUS-ERYTHEMATOSUS; LICHEN-PLANUS; B-CELL; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; RITUXIMAB TREATMENT; EFFICACY;
D O I
10.4317/medoral.19087
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Objectives: The main objectives are to present the different adverses effects of the immunomodulatory drugs that can impair the quality of life of the immunosupressed patients and study the impact of immunomodualtion on oral diseases. Immunomodulatory drugs have changed the treatment protocols of many diseases where immune functions play a central role, such as rheumatic diseases. Their effect on oral health has not been systematically investigated, however. Study Design: We review current data on the new immunomodulatory drugs from the oral health perspective based on open literature search of the topic. Results: These target specific drugs appear to have less drug interactions than earlier immunomodulating medicines but have nevertheless potential side effects such as activating latent infections. There are some data showing that the new immunomodulatory drugs may also have a role in the treatment of certain oral diseases such as lichen planus or ameliorating symptoms in Sjogren's syndrome, but the results have not been overly promising. Conclusions: In general, data are sparse of the effect of these new drugs vs. oral diseases and there are no properly powered randomized controlled trials published on this topic.
引用
收藏
页码:E24 / E31
页数:8
相关论文
共 47 条
  • [11] Oral erosive lichen planus treated with efalizumab
    Cheng, A
    Mann, C
    [J]. ARCHIVES OF DERMATOLOGY, 2006, 142 (06) : 680 - 682
  • [12] Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus
    Chun, Hye-Young
    Chung, Jae-Wook
    Kim, Hyoun-Ah
    Yun, Jeong-Moon
    Jeon, Ja-Young
    Ye, Young-Min
    Kim, Seung-Hyun
    Park, Hae-Sim
    Suh, Chang-Hee
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 2007, 27 (05) : 461 - 466
  • [13] Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study
    Dass, S.
    Bowman, S. J.
    Vital, E. M.
    Ikeda, K.
    Pease, C. T.
    Hamburger, J.
    Richards, A.
    Rauz, S.
    Emery, P.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (11) : 1541 - 1544
  • [14] del Valle AE, 2003, J PERIODONTOL, V74, P879
  • [15] A new inflammatory cytokine on the block: Re-thinking periodontal disease and the Th1/Th2 paradigm in the context of Th17 cells and IL-17
    Gaffen, S. L.
    Hajishengallis, G.
    [J]. JOURNAL OF DENTAL RESEARCH, 2008, 87 (09) : 817 - 828
  • [16] Primary Sjogren's syndrome: Pathophysiological, clinical and therapeutic advances
    Gottenberg, J. -E.
    [J]. JOINT BONE SPINE, 2009, 76 (06) : 591 - 594
  • [17] Clinically relevant drug interactions of current antifungal agents
    Gubbins, Paul O.
    Heldenbrand, Seth
    [J]. MYCOSES, 2010, 53 (02) : 95 - 113
  • [18] Adverse drug interactions in dentistry
    Hersh, Elliot V.
    Moore, Paul A.
    [J]. PERIODONTOLOGY 2000, 2008, 46 : 109 - 142
  • [19] Tocilizumab in Systemic Lupus Erythematosus Data on Safety, Preliminary Efficacy, and Impact on Circulating Plasma Cells From an Open-Label Phase I Dosage-Escalation Study
    Illei, Gabor G.
    Shirota, Yuko
    Yarboro, Cheryl H.
    Daruwalla, Jimmy
    Tackey, Edward
    Takada, Kazuki
    Fleisher, Thomas
    Balow, James E.
    Lipsky, Peter E.
    [J]. ARTHRITIS AND RHEUMATISM, 2010, 62 (02): : 542 - 552
  • [20] B cell or T cell-dominant recurrence after rituximab therapy in patients with SLE
    Iwata, Shigeru
    Saito, Kazuyoshi
    Tokunaga, Mikiko
    Tanaka, Yoshiya
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (10) : 1749 - 1750